Kory Wentworth Biography and Net Worth

Kory joined Entrada in 2020 and brings over 15 years of experience in the biotechnology sector and a passion for developing successful teams known for integrity and delivering high quality results and insightful analysis. Kory has led both commercial and clinical stage companies through high growth, global product launches, operational scale, and financial strategies.

Kory was previously Vice President of Finance and Treasurer, and Principal Accounting Officer, at bluebird bio, Inc. with responsibilities for global accounting and reporting, treasury, tax, and accounting operations. He has also held senior finance positions at Alexion Pharmaceuticals and consulting roles in PricewaterhouseCoopers LLP’s assurance and business advisory practice.

Kory has a BS in Accounting from Susquehanna University and is a Certified Public Accountant.

What is Kory James Wentworth's net worth?

The estimated net worth of Kory James Wentworth is at least $1.12 million as of November 21st, 2025. Wentworth owns 110,026 shares of Entrada Therapeutics stock worth more than $1,117,864 as of December 5th. This net worth approximation does not reflect any other investments that Wentworth may own. Learn More about Kory James Wentworth's net worth.

How old is Kory James Wentworth?

Wentworth is currently 45 years old. There are 3 older executives and no younger executives at Entrada Therapeutics. The oldest executive at Entrada Therapeutics is Dr. Natarajan Sethuraman Ph.D., Chief Scientific Officer, who is 62 years old. Learn More on Kory James Wentworth's age.

How do I contact Kory James Wentworth?

The corporate mailing address for Wentworth and other Entrada Therapeutics executives is , , . Entrada Therapeutics can also be reached via phone at 857-520-9158 and via email at [email protected]. Learn More on Kory James Wentworth's contact information.

Has Kory James Wentworth been buying or selling shares of Entrada Therapeutics?

Within the last three months, Kory James Wentworth has sold $88,921.80 of Entrada Therapeutics stock. Most recently, Kory James Wentworth sold 8,910 shares of the business's stock in a transaction on Friday, November 21st. The shares were sold at an average price of $9.98, for a transaction totalling $88,921.80. Following the completion of the sale, the chief financial officer now directly owns 110,026 shares of the company's stock, valued at $1,098,059.48. Learn More on Kory James Wentworth's trading history.

Who are Entrada Therapeutics' active insiders?

Entrada Therapeutics' insider roster includes John Crowley (Director), Dipal Doshi (CEO), Nathan Dowden (President and Chief Operating Officer), Kush Parmar (Director), Natarajan Sethuraman (Insider), and Kory Wentworth (CFO). Learn More on Entrada Therapeutics' active insiders.

Are insiders buying or selling shares of Entrada Therapeutics?

In the last twelve months, Entrada Therapeutics insiders bought shares 3 times. They purchased a total of 178,044 shares worth more than $1,352,567.90. In the last twelve months, insiders at the sold shares 13 times. They sold a total of 685,845 shares worth more than $5,867,281.75. The most recent insider tranaction occured on November, 21st when CFO Kory James Wentworth sold 8,910 shares worth more than $88,921.80. Insiders at Entrada Therapeutics own 8.1% of the company. Learn More about insider trades at Entrada Therapeutics.

Information on this page was last updated on 11/21/2025.